Literature DB >> 3903340

[Drug treatment of chronic glomerulonephritis: pro].

K Kühn, J Brodehl, K M Koch, U Helmchen.   

Abstract

This paper sets out the arguments for drug treatment of chronic glomerulonephritides (GN). Although the pathogenesis and mechanism of progression of chronic GN remained to be clarified, on the basis of controlled studies performed to date, there is a strong case to be made for an aggressive treatment approach to this disease spectrum. For instance, in patients with idiopathic membranous glomerulonephritis a six months treatment with chlorambucil (0.2 mg/KG/day) or prednisone (0.6 mg/KG/day) each given once a day over a period of three months has recently been shown to improve the outcome of the renal functional parameters after three years follow up. In another controlled trial a daily dose of 225 mg dipyridamole and 975 mg aspirin given over 12 months in patients with membrano-proliferative GN type I has been reported to normalize the increased platelet consumption rate and to stabilize the glomerular filtration rate. A third trial has demonstrated that the combined use of cyclophosphamide (100 mg/day) and prednisone (30 mg/day) over several months was superior to the use of prednisone alone (40 mg/day) in improving the long-term prognosis of diffuse-proliferative lupus nephritis (type IV, WHO). In some entities, however, as in IgA-nephritis there is still no evidence for a specific treatment improving the course of the chronic glomerular disease. Other therapeutic problems have to be solved: thus, in patients with minimal change nephropathy with a steroid dependent nephrotic syndrome the benefit of cyclophosphamide (given over three months) or of cyclosporin A is still being investigated. Furthermore, there is some evidence that progression of chronic GN, particularly that of glomerular sclerosing, can be prevented by a low protein diet. The role of eicosanoides and their inhibitors in this context has not yet been fully investigated. The different drug trials and new therapeutic concepts indicate a rapid development of chronic GN treatment. Therefore, a failure to treat actively is difficult to understand.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3903340     DOI: 10.1007/bf01738152

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  43 in total

1.  Eicosapentaenoic acid and IgA nephropathy.

Authors:  T Hamazaki; S Tateno; H Shishido
Journal:  Lancet       Date:  1984-05-05       Impact factor: 79.321

2.  Renal vein thrombosis and nephrotic syndrome. A prospective study of 36 adult patients.

Authors:  F Llach; A I Arieff; S G Massry
Journal:  Ann Intern Med       Date:  1975-07       Impact factor: 25.391

3.  Membranoproliferative glomerulonephritis. A prospective clinical trial of platelet-inhibitor therapy.

Authors:  J V Donadio; C F Anderson; J C Mitchell; K E Holley; D M Ilstrup; V Fuster; J H Chesebro
Journal:  N Engl J Med       Date:  1984-05-31       Impact factor: 91.245

4.  Therapeutic perspectives in mesangial IgA nephropathy.

Authors:  A R Clarkson; A J Woodroffe
Journal:  Contrib Nephrol       Date:  1984       Impact factor: 1.580

5.  Progression of renal failure in patients with renal disease of diverse etiology on protein-restricted diet.

Authors:  L Oldrizzi; C Rugiu; E Valvo; A Lupo; C Loschiavo; L Gammaro; N Tessitore; A Fabris; G Panzetta; G Maschio
Journal:  Kidney Int       Date:  1985-03       Impact factor: 10.612

6.  Immunosuppressive agents in renal transplantation.

Authors:  T B Strom
Journal:  Kidney Int       Date:  1984-09       Impact factor: 10.612

7.  Effect of dexamethasone on in vivo prostanoid production in the rabbit.

Authors:  A Náray-Fejes-Tóth; G Fejes-Tóth; C Fischer; J C Frölich
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

8.  Gonadal function in boys with steroid-responsive nephrotic syndrome treated with cyclophosphamide for short periods.

Authors:  R S Trompeter; P R Evans; T M Barratt
Journal:  Lancet       Date:  1981-05-30       Impact factor: 79.321

9.  Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin.

Authors:  G Ciabattoni; G A Cinotti; A Pierucci; B M Simonetti; M Manzi; F Pugliese; P Barsotti; G Pecci; F Taggi; C Patrono
Journal:  N Engl J Med       Date:  1984-02-02       Impact factor: 91.245

10.  The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children.

Authors: 
Journal:  J Pediatr       Date:  1981-04       Impact factor: 4.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.